Clinical Trial Update: Study Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) When Administered Via Subcutaneous Auto-injector vs Intramuscular Injection Via Needle and Syringe in Healthy Post-menopausal Women [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating subcutaneous auto-injector versus intramuscular injection for Makena, focusing on injection pain in healthy post-menopausal women; stud…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Healthy Post-menopausal Women

Drugs mentioned

• Makena (hydroxyprogesterone caproate)

Snippet

Sponsor: AMAG Pharmaceuticals, Inc. | Conditions: Assessing Injection Pain of Makena® (Hydroxyprogesterone Caproate Injection, 250 mg/mL) in Healthy Post-menopausal Women | Phase 3 | Status: TERMINATED | Results posted: 2018-12-12